ASRM Spotlight: AMH’s Expanding Therapeutic Potential Across Reproductive Medicine

Written By Sarah Faranda

Emerging research shows AMH is more than a marker of ovarian reserve, revealing an addressable therapeutic target with applications across menopause, oncofertility, and IVF stimulation. This article from Inside Reproductive Health provides an overview of new research presented at ASRM by David Pépin, PhD, showing compelling preclinical evidence that the AMH pathway can be therapeutically modulated, with potential applications in stimulation strategies, ovarian protection, and menopause. Read the article here or watch Pépin’s presentation here.

For more information on Granata Bio’s mission to innovate in reproductive health, view our pipeline.

Sarah Faranda
Previous

Zeb Younes, Chief Regulatory Officer, CMC at Granata Bio, featured in the January 2026 issue of Regulatory Rapporteur
Next

Granata Bio Reports Strong Enrollment Momentum in Pivotal Phase III GRACE Study of Investigational Gonadotropin for Assisted Reproductive Technology